B1680
Bradyzide di(trifluoroacetate) salt hydrate
≥98%
Synonym(s):
(S)-1-[4-(4-Benzhydrylthiosemicarbazido)-3-nitrobenzenesulfonyl]-pyrrolidine-2-carboxylic acid [2-[(2-dimethylaminoethyl)methylamino]ethyl] amide
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
| Pack Size | SKU | Availability | Price |
|---|---|---|---|
| 25 mg | Check Cart for Availability | $1,270.00 |
About This Item
Empirical Formula (Hill Notation):
C32H42N8O5S2 · 2C2HF3O2 · xH2O
Molecular Weight:
910.90 (anhydrous basis)
UNSPSC Code:
41106200
NACRES:
NA.32
MDL number:
$1,270.00
Check Cart for Availability
Biochem/physiol Actions
Potent, orally active, non-peptide B2 bradykinin receptor antagonist.
Features and Benefits
This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
1 of 1
This Item | |||
|---|---|---|---|
| assay ≥98% | assay ≥98% (HPLC) | assay ≥98% (HPLC) | assay ≥98% (HPLC) |
| form solid | form solid | form powder | form solid |
| Quality Level 100 | Quality Level 100 | Quality Level 100 | Quality Level 100 |
| storage temp. −20°C | storage temp. −20°C | storage temp. −20°C | storage temp. room temp |
| solubility H2O: >40 mg/mL | solubility DMSO: >5 mg/mL, H2O: insoluble | solubility H2O: 2 mg/mL, clear | solubility deionized water: ≥5 mg/mL |
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
G M Burgess et al.
British journal of pharmacology, 129(1), 77-86 (2000-02-29)
Bradyzide is from a novel class of rodent-selective non-peptide B(2) bradykinin antagonists (1-(2-Nitrophenyl)thiosemicarbazides). Bradyzide has high affinity for the rodent B(2) receptor, displacing [(3)H]-bradykinin binding in NG108-15 cells and in Cos-7 cells expressing the rat receptor with K(I) values of
Marielza Andrade Nunes et al.
Pharmaceuticals (Basel, Switzerland), 13(10) (2020-10-07)
Alzheimer's disease is mainly characterized by remarkable neurodegeneration in brain areas related to memory formation. This progressive neurodegeneration causes cognitive impairment, changes in behavior, functional disability, and even death. Our group has demonstrated changes in the kallikrein-kinin system (KKS) in
Global Trade Item Number
| SKU | GTIN |
|---|---|
| B1680-25MG | 04061832269276 |
| B1680-5MG | 04061833426302 |